Search Results - "Stephenson, Regan"

Engineered microscale hydrogels for drug delivery, cell therapy, and sequencing by Wechsler, Marissa E., Stephenson, Regan E., Murphy, Andrew C., Oldenkamp, Heidi F., Singh, Ankur, Peppas, Nicholas A.

“…Engineered microscale hydrogels have emerged as promising therapeutic approaches for the treatment of various diseases. These microgels find wide application…”
Get full text

Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes by Scholze, Hanna, Stephenson, Regan E., Reynolds, Raymond, Shah, Shivem, Puri, Rishi, Butler, Scott D., Trujillo-Alonso, Vicenta, Teater, Matthew R., van Besien, Herman, Gibbs-Curtis, Destini, Ueno, Hideki, Parvin, Salma, Letai, Anthony, Mathew, Susan, Singh, Ankur, Cesarman, Ethel, Melnick, Ari, Giulino-Roth, Lisa

“…Molecular alterations in the histone methyltransferase EZH2 and the antiapoptotic protein Bcl-2 frequently co-occur in diffuse large B-cell lymphoma (DLBCL)…”
Get full text

Drug discovery and therapeutic delivery for the treatment of B and T cell tumors by Stephenson, Regan, Singh, Ankur

“…Hematological malignancies manifest as lymphoma, leukemia, and myeloma, and remain a burden on society. From initial therapy to endless relapse-related…”
Get full text

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes by Gibbs, Destini, Van Besien, Herman, Regan, Stephenson, Singh, Ankur, Teater, Matthew, Cesarman, Ethel, Melnick, Ari, Roth, Lisa Giulino

“…DLCBL has recently been classified into genetically defined subtypes based on groupings of particular genetic lesions (Chapuy et al, Nat Med 2018; Schmitz et…”
Get full text

Microfluidic-aided genotyping of zebrafish in the first 48 h with 100 % viability by Samuel, Raheel, Stephenson, Regan, Roy, Paula, Pryor, Rob, Zhou, Luming, Bonkowsky, Joshua L., Gale, Bruce K.

“…This paper introduces an innovative method for genotyping 1–2 days old zebrafish embryos, without sacrificing the life/health of the embryos. The method…”
Get full text

Abstract PO-53: Combined EZH2 and BCL2 inhibitors as precision therapy for genetically defined DLBCL subtypes by Scholze, Hanna, Stephenson, Regan E., Reynolds, Raymond, Shah, Shivem, Puri, Rishi, Teater, Matthew R., van Besien, Herman, Gibbs-Curtis, Destini, Ueno, Hideki, Parvin, Salma, Letai, Anthony G., Mathew, Susan, Singh, Ankur, Cesarman, Ethel, Melnick, Ari, Giulino-Roth, Lisa

“…Abstract Molecular alterations in the histone methyltransferase EZH2 and the antiapoptotic protein BCL2 frequently co-occur in diffuse large B-cell lymphoma…”
Get full text